

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Securities Code: 4577

August 4, 2025

To our shareholders:

Hiroshi Matsumori, President and CEO
Daito Pharmaceutical Co., Ltd.
326 Yokamachi, Toyama City, Toyama Prefecture

Notice of the 83rd Annual General Meeting of Shareholders

We hereby announce the 83rd Annual General Meeting of Shareholders of Daito Pharmaceutical Co., Ltd. (the “Company”), which will be held as indicated below.

When convening this general meeting of shareholders, the Company takes measures for providing in electronic format the information that constitutes the content of reference documents for the shareholders meeting, etc. (items for which measures for providing information in electronic format will be taken). This information is posted on each of the following websites, so please access either of those websites to confirm the information.

The Company’s website:

<https://www.daitonet.co.jp/ir/agm.html> (in Japanese)

Website for posted informational materials for the general meeting of shareholders:

<https://d.sokai.jp/4577/teiji/> (in Japanese)

TSE website (Listed Company Search):

<https://www2.jpx.co.jp/tseHpFront/JJK010010Action.do?Show=Show> (in Japanese)

(Access the TSE website by using the internet address shown above, enter “Daito” in “Issue name (company name)” or the Company’s securities code “4577” in “Code,” and click “Search.” Then, click “Basic information” and select “Documents for public inspection/PR information.” Under “Filed information available for public inspection,” click “Click here for access” under “[Notice of General Shareholders Meeting /Informational Materials for a General Shareholders Meeting].”)

If you are unable to attend the meeting in person, you can exercise your voting rights in writing (by mail) or by electromagnetic method (via the Internet, etc.) in accordance with “Guidance on Exercising Voting Rights” (in Japanese only); so please read the Reference Documents for the General Meeting of Shareholders and exercise your voting rights by no later than 5:20 p.m. on Wednesday, August 27, 2025 (JST).

1. Date and time: Thursday, August 28, 2025 at 10:30 a.m. (JST) (Reception commences at 9:30 a.m.)

2. Venue: 2F, Multi-purpose Room, Toyama International Conference Center
1-2 Ote-machi Toyama City, Toyama

3. Purpose of the Meeting

Matters to be reported:

1. The Business Report and Consolidated Financial Statements, as well as the audit reports of Consolidated Financial Statements by the Financial Auditor and the Audit and Supervisory Committee for the 83rd Fiscal Year (from June 1, 2024 to May 31, 2025)
2. The Non-consolidated Financial Statements for the 83rd Fiscal Year (from June 1, 2024 to May 31, 2025)

Matter to be resolved:

Proposal 1 Election of Five Board Directors (Excluding Board Directors Who Are Audit and Supervisory Committee Members)

Proposal 2 Election of Three Board Directors Who Are Audit and Supervisory Committee Members

4. Matters decided concerning the convocation:

- When you attend the meeting in person, you are kindly requested to present the voting form at the reception desk.
- For this general meeting of shareholders, we have delivered paper-based documents stating the items subject to measures for electronic provision to all shareholders, regardless of whether or not they have requested them.

Among the items subject to measures for electronic provision, in accordance with the provisions of laws and regulations and Article 17 of the Articles of Incorporation of the Company, the following items are not provided in the paper-based documents delivered.

- 1) "Systems for Ensuring the Propriety of Business Activities and the Status of its Implementation" in the Business Report
- 2) The Consolidated Statement of Changes in Equity and the Notes to the Consolidated Financial Statements
- 3) The Non-consolidated Statement of Changes in Equity and the Notes to the Non-consolidated Financial Statements

Accordingly, the Business Report, Consolidated Financial Statements and Non-Consolidated Financial Statements included in the documents are part of the documents audited by the Financial Auditor in preparing the Accounting Audit Report and by the Audit and Supervisory Committee in preparing the Audit Report.

- If revisions to the items subject to measures for electronic provision arise, a notice of the revisions and the details of the items before and after the revisions will be posted on each of the websites mentioned on page 1.
- If voting rights are exercised in writing (by mail), when the voting form shows neither approval nor disapproval of a proposal, it shall be counted as approval of the proposal.

Reference Documents for the General Meeting of Shareholders

Proposal and Reference Information

Proposal 1 Election of Five Board Directors (Excluding Board Directors Who Are Audit and Supervisory Committee Members)

The terms of office of all five Board Directors (excluding Board Directors who are Audit and Supervisory Committee Members; hereinafter the same shall apply in this proposal) will expire at the conclusion of this meeting. Therefore, following deliberation and reporting by the Nomination and Compensation Advisory Committee, the Company proposes the election of five Board Directors pursuant to the resolution of the Board of Directors.

The candidates for Board Director are as follows:

Candidate No.	Name (Date of birth)	Career summary, and position and responsibility in the Company (Significant concurrent positions outside the Company)	Number of the Company's shares owned
1	Yasunobu Otsuga (October 30, 1950)	<div> <div>Mar. 1975</div> <div>Joined the Company (former Daito Trading Co., Ltd.)</div> </div> <div> <div>June 1984</div> <div>Director of Sales Planning Department</div> </div> <div> <div>July 1986</div> <div>Board Director</div> </div> <div> <div>June 2005</div> <div>Senior Board Director</div> </div> <div> <div>Aug. 2007</div> <div>Board Director and Executive Corporate Officer, Head of Administrative Division</div> </div> <div> <div>June 2010</div> <div>Board Director and Executive Corporate Officer, Director of Corporate Planning</div> </div> <div> <div>Aug. 2011</div> <div>Representative Board Director, Executive Vice President</div> </div> <div> <div>Aug. 2012</div> <div>President and CEO</div> </div> <div> <div>Aug. 2022</div> <div>Representative Board Director, President of Daiwa Pharmaceutical Co., Ltd.</div> </div> <div> <div>Jan. 2024</div> <div>Board Director</div> </div> <div> <div>Aug. 2024</div> <div>Chairman of the Company (current position)</div> </div>	32,805 shares
	Reason for nomination as candidate Yasunobu Otsuga has been in charge of the Company's management for many years, has extensive experience and knowledge of the Company's business and management overall, exercises leadership, oversees management, and performs his duties appropriately; therefore, the Company proposes to continue his election as Board Director.		

Candidate No.	Name (Date of birth)	Career summary, and position and responsibility in the Company (Significant concurrent positions outside the Company)	Number of the Company's shares owned
2	Hiroshi Matsumori (July 24, 1956)	<p>Apr. 1982 Joined Taito Pfizer Co. (currently Pfizer Japan Inc.)</p> <p>Apr. 1994 Product Manager of Antimycotic Agent Group, Medicine Marketing Department</p> <p>Dec. 1996 General Manager of Clinical Development Department, Clinical Development Division, Research & Development Headquarters (in charge of medicine for infectious disease)</p> <p>May 2000 General Manager and Chief of Headquarters of Drug Development Regulatory Affairs Department</p> <p>Mar. 2004 Seconded to La Jolla Research Institute of Pfizer Inc., Global Regulatory Leader</p> <p>Sept. 2008 Executive Officer, General Manager of Corporate Planning Division of Pfizer Japan Inc.</p> <p>Mar. 2009 Executive Officer, Head of Corporate Affairs Quality Assurance Department and Marketing Supervisor-General</p> <p>Dec. 2009 Director and Executive Officer, Head of the Established Pharmaceutical Business</p> <p>Apr. 2013 Director and Executive Officer, Vice President in charge of Strategy for the Established Pharmaceutical Business in Asia-Pacific Region (retired in December 2013)</p> <p>Dec. 2013 Representative Director, President of SBI Biotech Co., Ltd. (retired in September 2014)</p> <p>Oct. 2014 Representative of Matsumori Pharma Consulting</p> <p>Apr. 2016 CEO and President of Teva Pharma Ltd. (currently Teva Takeda Pharma Ltd.)</p> <p>Apr. 2017 CEO and President of Teva Takeda Yakuhin Ltd.</p> <p>Oct. 2021 Representative Director and President, and CEO, of Teva Takeda Pharma Ltd. (retired in April 2023)</p> <p>Oct. 2021 Representative Director and President, and CEO, of Teva Takeda Yakuhin Ltd. (retired in April 2023)</p> <p>July 2023 Joined the Company</p> <p>Aug. 2023 Board Director and Executive Vice President, in charge of Business Strategy, and Head of Administrative Division</p> <p>Jan. 2024 Representative Board Director, Executive Vice President, in charge of Business Strategy, and Head of Administrative Division</p> <p>Aug. 2024 President</p> <p>Jan. 2025 President and CEO (current position)</p>	14,300 shares
<p>Reason for nomination as candidate</p> <p>Hiroshi Matsumori has extensive experience and knowledge through longstanding participation in research and development operations at pharmaceuticals companies and as a senior member of corporate management. The Company proposes to continue his election as a Board Director, as he has made use of this extensive experience and knowledge to appropriately perform his duties as a Board Director of the Company, including supervising the decision-making and business execution of the Company's overall management, and has contributed to the enhancement of the Company's corporate value.</p>			

Candidate No.	Name (Date of birth)	Career summary, and position and responsibility in the Company (Significant concurrent positions outside the Company)		Number of the Company's shares owned
3	Kazushige Hizume (February 25, 1962)	Apr. 1985	Joined the Company (former Daito Trading Co., Ltd.)	21,095 shares
		June 2001	Manager of API Sales Department, API Business Division	
		June 2006	Director of Prescription Medicine Department, Pharmaceutical Business Division, and Deputy Director of API Sales Department, API Business Division	
		Apr. 2009	Director of Contract Promotion Department, Pharmaceutical Business Division	
		June 2010	Director of API Sales Department, API Business Division	
		June 2014	Director of Prescription Medicine Department, Pharmaceutical Business Division	
		Aug. 2016	Executive Officer, Deputy Head of Pharmaceutical Business Division and Director of Prescription Medicine Department	
		Aug. 2018	Board Director and Executive Officer, Head of Sales Headquarters and Head of Pharmaceutical Business Division	
		June 2022	Board Director and Senior Corporate Officer, Head of Sales Headquarters and Head of Pharmaceutical Business Division (current position)	
		Significant concurrent positions outside the Company Board Director of Daito Pharmaceutical (China) Co., Ltd.		
Reason for nomination as candidate Kazushige Hizume has extensive experience and wide-ranging expertise from his many years of sales activities in the Company's API and pharmaceutical business divisions. The Company proposes to continue his election as Board Director, as he has appropriately performed his duties as a Board Director of the Company and has contributed to the enhancement of the Company's corporate value.				

Candidate No.	Name (Date of birth)	Career summary, and position and responsibility in the Company (Significant concurrent positions outside the Company)	Number of the Company's shares owned
4	Toru Ishida (December 14, 1960)	<p>Apr. 1985 Joined Takeda Pharmaceutical Company Limited</p> <p>Apr. 2008 General Manager of Chemical Development Laboratories, CMC Research Center, Pharmaceutical Production Division</p> <p>Apr. 2010 General Manager of Production Control Department, Pharmaceutical Production Division</p> <p>Apr. 2012 General Manager of Production Planning Department, Pharmaceutical Production Division</p> <p>July 2013 Head of Hikari Plant, Pharmaceutical Production Division</p> <p>Apr. 2015 Head of Hikari Plant, Global Manufacturing and Supply Japan and Asia (retired in March 2018)</p> <p>Apr. 2018 Representative Director and President of Takeda Healthcare Products Co., Ltd. (currently Alinamin Pharma Tech Co., Ltd.) (retired in October 2022)</p> <p>Nov. 2022 Joined the Company</p> <p>Sept. 2023 Executive Officer, Deputy Head of Production Division</p> <p>Jan. 2024 Executive Officer, Head of Production Division and General Manager of Environmental Safety Department</p> <p>June 2024 Executive Officer, Head of Production Division, General Manager of Pharmaceutical Production Unit, and General Manager of Environmental Safety Department</p> <p>Aug. 2024 Board Director, Executive Officer, Head of Production Division, General Manager of Pharmaceutical Production Unit, and General Manager of Environmental Safety Department (current position)</p>	0 shares
<p>Reason for nomination as candidate</p> <p>Toru Ishida has extensive experience and wide-ranging expertise through longstanding participation in research and development operations and manufacturing operations at a pharmaceuticals company and as a senior member of corporate management. The Company proposes to continue his election as Board Director as he has made use of this extensive experience and knowledge to appropriately perform his duties as a Board Director of the Company and has contributed to the enhancement of the Company's corporate value.</p>			

Candidate No.	Name (Date of birth)	Career summary, and position and responsibility in the Company (Significant concurrent positions outside the Company)	Number of the Company's shares owned
5	Kimiko Komatsu (June 20, 1958)	<p>Apr. 1980 Joined Daido Hospital, Kojunkai Social Medical Corporation</p> <p>Aug. 1996 Joined Hokuriku Health Service Association</p> <p>Oct. 2010 Counselor for occupational health and Promoter for mental health measures of Toyama Occupational Health Support Center (current position)</p> <p>Dec. 2020 Representative of Mind Plus Toyama (current position)</p> <p>Aug. 2022 Outside Board Director of the Company (current position)</p> <p>Significant concurrent positions outside the Company Representative of Mind Plus Toyama</p>	0 shares
<p>Reason for nomination as candidate as outside Board Director and outline of expected roles</p> <p>Although Kimiko Komatsu has never been involved in the management of a company, the Company expects her to continue to contribute to the enhancement of the Company's corporate value from a professional and objective perspective, particularly with respect to employee labor issues, comprehensive mental health measures, and building a better workplace environment, utilizing her extensive experience and knowledge as a licensed industrial counselor and certified psychotherapist. The Company therefore proposes her as a candidate for outside Board Director.</p>			

- Notes:
- The number of the Company's shares held by each candidate is as of the end of the fiscal year under review (May 31, 2025) prior to the stock split on June 1, 2025.
 - There is no special interest between any of the candidates and the Company.
 - Kimiko Komatsu is a candidate for outside Board Director.
 - Policies and Procedures for Nominating Candidates for Board Directors

In determining each candidate, the Company considers candidates who can demonstrate strength in the management of each business field in a wide range of business areas, and who possess excellent character, knowledge, and high ethical standards, with due consideration given to the balance between the candidates' suitability for management and administration.

In order to enhance corporate governance by strengthening the fairness, transparency, and objectivity of procedures related to determining candidates for Board Directors, etc., the Nomination and Compensation Advisory Committee was established as an advisory body to the Board of Directors, and the Board of Directors respects the recommendations and proposals made by the Nomination and Compensation Advisory Committee to the maximum extent possible when determining candidates.

The Nomination and Compensation Advisory Committee, chaired by an independent outside Board Director, is consulted by and reports to the Board of Directors the results of its review and evaluation of candidates for Board Directors in accordance with fair and transparent procedures, based on an appropriate assessment of the Company's performance and other factors, for decision by the Board of Directors.
 - Opinion of the Audit and Supervisory Committee

The election of Board Directors (excluding Board Directors who are Audit and Supervisory Committee Members) was based on the Nomination and Compensation Advisory Committee, chaired by an Audit and Supervisory Committee Member who is also an outside Board Director, evaluating the candidates' qualifications, etc., based on an appropriate assessment of the Company's performance, etc. Therefore, the Audit and Supervisory Committee has determined that there are no special matters that require a statement of opinion at the General Meeting of Shareholders as provided for in the Companies Act.
 - Outline of Directors and Officers Liability Insurance Agreement

The Company has entered into a Directors and Officers Liability Insurance Agreement with an insurance company as provided for in Article 430-3, paragraph (1) of the Companies Act, with the Board Directors as insured, and plans to renew and continue such agreement. If each candidate is elected, each of them will be the insured under the said agreement. The outline of such agreement is that, under the said agreement, the insurance company covers losses that may arise from the insured's assumption of liability incurred in the course of the performance of duties as an officer or a person at a certain position, or receipt of claims pertaining to the pursuit of such liability.

The agreement does not cover the payment of claims in the event of liability for damages that may arise from an officer's illegal act or in the event that the Company pursues liability for damages against the officer, and also sets a limit on the amount of compensation to be paid, in order to ensure that the officer's performance of his or her duties is not impaired.

7. Limited liability agreements with outside Board Director

The Company has entered into an agreement with Kimiko Komatsu to limit her liability for damages under Article 423, paragraph (1) of the Companies Act as provided for in Article 427, paragraph (1) of the said Act, in order to enable her to fully perform her expected roles, and will plan to renew such agreement if her reelection is approved. The maximum amount of liability for damages under the said agreement is the amount stipulated in Article 425, paragraph (1) of the Companies Act.

8. Kimiko Komatsu satisfies the requirements for an independent officer as provided for by the Tokyo Stock Exchange. The Company appointed Kimiko Komatsu as an independent officer, and notified the said exchange of such appointment. Provided she is re-elected as proposed, she will continue her service for the Company as an independent officer.
9. Kimiko Komatsu is currently an outside Board Director of the Company. Upon the conclusion of this meeting, Kimiko Komatsu will have served three years since her appointment.

Proposal 2**Election of Three Board Directors Who Are Audit and Supervisory Committee Members**

The terms of office of all four Board Directors who are Audit and Supervisory Committee Members will expire at the conclusion of this meeting. Therefore, following deliberation and reporting by the Nomination and Compensation Advisory Committee, the Company proposes the election of three Board Directors pursuant to the resolution of the Board of Directors.

The proposal has been agreed upon by the Audit and Supervisory Committee.

The candidates for Board Director who are Audit and Supervisory Committee Members are as follows:

The candidates for Board Director who are Audit and Supervisory Committee Members are as follows:			
Candidate No.	Name (Date of birth)	Career summary, and position and responsibility in the Company (Significant concurrent positions outside the Company)	Number of the Company's shares owned
1	Ichizo Yamamoto (November 14, 1956)	Apr. 1991 Registered as attorney at law (Toyama Bar Association) June 2008 Outside Audit & Supervisory Board Member of Richell Corporation (current position) Aug. 2012 Outside Audit & Supervisory Board Member of the Company Aug. 2015 Outside Board Director and Outside Audit and Supervisory Committee Member (current position) Significant concurrent positions outside the Company Director of Yamamoto Ichizo Law Office Outside Audit & Supervisory Board Member of Richell Corporation	0 shares
		Reason for nomination as candidate as outside Board Director and outline of expected roles Although Ichizo Yamamoto has never been involved in corporate management, he possesses expertise, experience, and good knowledge of corporate legal affairs as an attorney at law and leverages sufficient insight for supervision of corporate management to carry out audit activities at the Company's Audit and Supervisory Committee and provide advice on overall management from objective viewpoints. The Company expects him to continue advising and supervising the Company's management based on his rich knowledge and experience, and judges that he will continue to fulfill his duties at the Audit and Supervisory Committee.	
2	Atsushi Saino (July 4, 1973)	Apr. 2006 Joined Specific Medical Corporation Foundation Goseikai July 2009 Managing Director Feb. 2010 Director (current position) Aug. 2017 Outside Board Director and Outside Audit and Supervisory Committee Member of the Company (current position) Significant concurrent positions outside the Company Director of Specific Medical Corporation Foundation Goseikai	0 shares
		Reason for nomination as candidate as outside Board Director and outline of expected roles Although Atsushi Saino has never been involved in corporate management, he leverages his knowledge and experience as the manager of a medical corporation to carry out audit activities at the Company's Audit and Supervisory Committee and provide advice on overall management from objective viewpoints. The Company expects him to continue advising and supervising the Company's management based on his rich knowledge and experience, and judges that he will continue to fulfill his duties at the Audit and Supervisory Committee.	

Candidate No.	Name (Date of birth)	Career summary, and position and responsibility in the Company (Significant concurrent positions outside the Company)	Number of the Company's shares owned
3	New election Minori Uchida (July 8, 1970)	<p>Apr. 1993 Joined The Bank of Tokyo, Ltd. (currently MUFG Bank, Ltd.)</p> <p>Feb. 2002 Europe Office, Foreign Exchange Fund Division</p> <p>Apr. 2010 Senior Analyst of Global Markets Service Division</p> <p>May 2012 Chief Analyst of Global Markets Planning Division</p> <p>Apr. 2022 Associate Professor of Faculty of Commerce, Takachiho University</p> <p>Apr. 2024 Professor of Faculty of Commerce (current position)</p> <p>Significant concurrent positions outside the Company</p> <p>Professor of Faculty of Commerce, Takachiho University</p> <p>Foreign Exchange Analyst of The FDALco, Ltd.</p>	0 shares
<p>Reason for nomination as candidate as outside Board Director and outline of expected roles</p> <p>Minori Uchida possesses extensive knowledge and rich experience in international finance, as well as high-level analysis capacity evaluated to be Japan's top-class by finance magazines. The Company judges that he will be able to provide objective advice on the Company's management strategies which are closely related to state finance, political system, and domestic and overseas financial markets, and appropriately supervise corporate governance, and therefore proposes his election.</p>			
<p>Message to shareholders</p> <p>Daito is a life infrastructure company that supports health of many people as a pharmaceutical contract manufacturer based on research and development. Leveraging my former experience in international finance analysis, sales strategy planning, and team management in Japan and overseas, as well as my current work of developing human resources, I will strive to supervise execution of management strategies at Daito from an objective standpoint and contribute to enhancement of corporate value.</p>			

- Notes:
1. There is no special interest between any of the candidates and the Company.
 2. Ichizo Yamamoto, Atsushi Saino, and Minori Uchida are candidates for outside Board Directors.
 3. Policies and Procedures for Nominating Candidates for Board Directors (who are Audit and Supervisory Committee Members)
In determining each candidate, the Company considers candidates who can demonstrate strength in the management of each business field in a wide range of business areas, and who possess excellent character, knowledge, and high ethical standards, with due consideration given to the balance between the candidates' suitability for management and administration.
In order to enhance corporate governance by strengthening the fairness, transparency, and objectivity of procedures related to determining candidates for Board Directors, etc., the Nomination and Compensation Advisory Committee was established as an advisory body to the Board of Directors on December 9, 2021, and the Board of Directors respects the recommendations and proposals made by the Nomination and Compensation Advisory Committee to the maximum extent possible when determining candidates. The Nomination and Compensation Advisory Committee, chaired by an independent outside Board Director, is consulted by and reports to the Board of Directors the results of its review and evaluation of candidates for Board Directors in accordance with fair and transparent procedures, based on an appropriate assessment of the Company's performance and other factors, for decision by the Board of Directors.
 4. Ichizo Yamamoto and Atsushi Saino are currently outside Board Directors who are Audit and Supervisory Committee Members of the Company. Upon the conclusion of this meeting, Ichizo Yamamoto and Atsushi Saino will have served ten years and eight years since their appointment, respectively.
 5. Limited liability agreements with outside Board Directors
The Company has entered into an agreement with Ichizo Yamamoto and Atsushi Saino to limit their liability for damages under Article 423, paragraph (1) of the Companies Act as provided for in Article 427, paragraph (1) of the said Act, in order to enable them to fully perform their expected roles, and will plan to renew such agreement if their reelection is approved. The Company will also enter into the said agreement with Minori Uchida if his election is approved. The maximum amount of liability for damages under the said agreement is the amount stipulated in Article 425, paragraph (1) of the Companies Act.

6. Ichizo Yamamoto and Atsushi Saino satisfy the requirements for an independent officer as provided for by the Tokyo Stock Exchange. The Company appointed them as independent officers, and notified the said exchange of such appointment. Provided they are re-elected as proposed, they will continue their service for the Company as independent officers. If Minori Uchida is elected as proposed, the Company will also appoint him as an independent officer and notify the said exchange of such appointment.
7. Outline of Directors and Officers Liability Insurance Agreement
The Company has entered into a Directors and Officers Liability Insurance Agreement with an insurance company as provided for in Article 430-3, paragraph (1) of the Companies Act, with the Board Directors as insured, and plans to renew and continue such agreement. If each candidate is elected, each of them will be the insured under the said agreement. The outline of such agreement is that, under the said agreement, the insurance company covers losses that may arise from the insured's assumption of liability incurred in the course of the performance of duties as an officer or a person at a certain position, or receipt of claims pertaining to the pursuit of such liability.
The agreement does not cover the payment of claims in the event of liability for damages that may arise from an officer's illegal act or in the event that the Company pursues liability for damages against the officer, and also sets a limit on the amount of compensation to be paid, in order to ensure that the officer's performance of his or her duties is not impaired.

[Reference] Skills Matrix of Board Directors and Audit and Supervisory Committee Members

If the proposal is approved as proposed, the composition of the Company's Board Directors and Audit and Supervisory Committee Members and their main areas of knowledge and experience will be as follows.

Name	Audit and Supervisory Committee Members	Outside	Independent officers	Corporate management	Industry insight	Finance and accounting	Internationality
Yasunobu Otsuga				○	○	○	
Hiroshi Matsumori				○	○		○
Kazushige Hizume					○		
Toru Ishida				○	○		○
Kimiko Komatsu		○	○				
Ichizo Yamamoto	○	○	○				
Atsushi Saino	○	○	○	○	○		
Minori Uchida	○	○	○			○	○

Name	Legal affairs and risk management	HR development and labor	Marketing and sales	Technology and R&D	Production	Quality assurance
Yasunobu Otsuga			○	○	○	○
Hiroshi Matsumori		○	○	○		○
Kazushige Hizume			○			
Toru Ishida	○			○	○	○
Kimiko Komatsu		○				
Ichizo Yamamoto	○					
Atsushi Saino						
Minori Uchida		○				

(Note) The above does not cover all of the knowledge and experience possessed by each person.